JOHN WRANGLE: MATCH stands for Molecular Analysis for Therapy Choice. The MATCH trial is remarkably different from other clinical trials. The typical design of a clinical trial has been to, say, a patient with lung cancer or colon cancer or breast cancer and to use one type of therapy for a very specific population. This trial allows a diverse set of malignancies to potentially be eligible for treatment with a wide variety of agents.

So the purpose of this trial is to find a very diverse population of patients with cancer and match that with a similarly diverse number of drugs or anti-cancer agents. The MATCH trial targets patients with any kind of solid tumor or lymphoma or multiple myeloma. Patients enrolled in the trial will undergo a molecular analysis of their tumor in order to determine what genetic abnormalities are harbored within the tumor and to pair a therapy that we think is going to be effective for that particular abnormality with the patient.

This allows patients access to drugs despite the fact that you can't necessarily design a clinical trial in one particular malignancy for that molecular abnormality. The purpose of this trial is to create a large multi-arm trial that will allow a diverse set of malignancies to be eligible for a diverse set of drugs.